Continuing the Conversation: PARP Inhibitor Combination Therapies to Improve Outcomes for Patients with mCRPC

Aug 1, 2023 | Prostate

2) The expert faculty for this symposium was led by program chair @alantanmd Director of GU Medical Oncology @RushMedical, along with @AlanBryce9 of @MayoCancerCare @MayoClinic, & #MahaHussein MD of @NorthwesternMed. The program can be reviewed in 📽️at...

The Advancing Role of PARP Inhibitor Combination Therapies to Improve Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Jul 26, 2023 | Prostate

2) The expert faculty for this symposium was led by program chair @alantanmd Director of GU Medical Oncology @RushMedical, along with @AlanBryce9 of @MayoCancerCare @MayoClinic, & #MahaHussein MD of @NorthwesternMed. The program can be reviewed in 📽️at...